Loading clinical trials...

Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD | Clinical Trials | Clareo Health

COMPLETED

Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD

Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in Children With Down Syndrome With and Without Congenital Heart Disease

NCT05191654•Atılım University

View on ClinicalTrials.gov

Summary

Congenital heart diseases (CHD) are detected in 40-60% of individuals with Down syndrome (DS) and increase the risk of developmental delay in the presence of syndromes. The aim of the study was to compare cardiopulmonary parameters, gross motor development and hand grip strength in DS children with and without CHD. Demographic variables, cardiopulmonary parameters and echocardiographic values were recorded. Gross motor development was evaluated with Gross Motor Function Measure (GMFM-88). Hand grip strength was measured with the Baseline Pneumatic Bulb Dynamometer.

Eligibility

Age

0 - 5 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Diagnosed with Down syndrome as a result of genetic analysis,
•For the congenital heart disease group; undergoing cardiac surgery at least 6 months before the evaluation, diagnosed as CHD by a pediatric cardiologist based on echocardiographic findings,
•For the group without congenital heart disease, patients who have not undergone cardiac surgery, are asymptomatic with a septal defect smaller than 4-5 mm, are expected to close, and are hemodynamically normal by a pediatric cardiologist,
•Children whose families were informed about the study and gave written consent to participate in the study were included in the study.

Exclusion Criteria

•Having another genetic abnormality other than Down syndrome,
•undergoing surgery other than cardiac surgery,
•Having an orthopedic or neurological problem,
•Respiratory support,
•With atlantoaxial instability,
•Children with hematological disease were not included in the study.

Locations (1)

Atılım University

Ankara, Turkey (Türkiye)

Key Dates

Start Date

October 1, 2020

Primary Completion Date

June 30, 2021

Completion Date

June 30, 2021

Last Updated

January 13, 2022

Enrollment

ACTUAL participants

Conditions

Congenital Heart DefectsDown SyndromeGross Motor Development Delay

Interventions

evaluation of cardiopulmonary parameters, gross motor development and hand grip strength

DIAGNOSTIC_TEST

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more

View study

RECRUITINGPHASE3

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

NCT07234695

Down SyndromeDown Syndrome (DS)+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigation of Cardiopulmonary Parameters, Motor Development and Muscle Strength in DS With and Without CHD

Inclusion Criteria

Exclusion Criteria

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Effects of Vojta Therapy on Functional Mobility and Gait Parameters in Children With Down Syndrome

Effects of Powerball in Children With Down Syndrome

Using Technologies to Promote HEalthy Lifestyles in Adolescents With Intellectual Disabilities

Measuring Aided Language Development